Crinetics Pharmaceuticals/$CRNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Ticker
$CRNX
Sector
Primary listing
Employees
594
Headquarters
Website
CRNX Metrics
BasicAdvanced
$3.9B
-
-$4.95
0.24
-
Price and volume
Market cap
$3.9B
Beta
0.24
52-week high
$57.99
52-week low
$24.10
Average daily volume
1M
Financial strength
Current ratio
12.323
Quick ratio
12.09
Long term debt to equity
4.239
Total debt to equity
4.893
Profitability
EBITDA (TTM)
-512.879
Gross margin (TTM)
-4,228.66%
Net profit margin (TTM)
-6,046.22%
Operating margin (TTM)
-6,714.77%
Effective tax rate (TTM)
-0.04%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-25.22%
Return on equity (TTM)
-40.17%
Valuation
Price to revenue (TTM)
455.623
Price to book
3.59
Price to tangible book (TTM)
3.59
Price to free cash flow (TTM)
-9.139
Free cash flow yield (TTM)
-10.94%
Free cash flow per share (TTM)
-4.079
Growth
Revenue change (TTM)
640.71%
Earnings per share change (TTM)
33.93%
3-year revenue growth (CAGR)
17.56%
3-year earnings per share growth (CAGR)
16.20%
What the Analysts think about CRNX
Analyst ratings (Buy, Hold, Sell) for Crinetics Pharmaceuticals stock.
CRNX Financial Performance
Revenues and expenses
CRNX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Crinetics Pharmaceuticals stock?
Crinetics Pharmaceuticals (CRNX) has a market cap of $3.9B as of March 17, 2026.
What is the P/E ratio for Crinetics Pharmaceuticals stock?
The price to earnings (P/E) ratio for Crinetics Pharmaceuticals (CRNX) stock is 0 as of March 17, 2026.
Does Crinetics Pharmaceuticals stock pay dividends?
No, Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders as of March 17, 2026.
When is the next Crinetics Pharmaceuticals dividend payment date?
Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals (CRNX) has a beta rating of 0.24. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.